Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02621151 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
A Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder, sponsored by NYU Langone Health.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02621151 is a Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 60 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT02621151, a Phase 2 study of Muscle-invasive Urothelial Cancer of the Bladder, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION External Beam Radiation Therapy
- DRUG Gemcitabine
- PROCEDURE Transurethral Resection of Bladder Tumor
Study Locations (5)
New York
- NYU Perlmutter Cancer Center - New York
- Memorial Sloan Kettering - New York
Illinois
- University of Chicago - Chicago
Michigan
- University of Michigan Health System - Ann Arbor
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-08-11 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02621151
The ClinicalTrials.gov registry entry for NCT02621151 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle-invasive Urothelial Cancer of the Bladder appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02621151 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT02621151 about?
NCT02621151 is a clinical study titled "Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder". This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.
What is the current status of trial NCT02621151?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-08-11. Estimated completion is 2025-12.
What conditions does trial NCT02621151 study?
This clinical trial studies the following conditions: Muscle-invasive Urothelial Cancer of the Bladder.
What interventions are being tested in trial NCT02621151?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), External Beam Radiation Therapy (RADIATION), Gemcitabine (DRUG), Transurethral Resection of Bladder Tumor (PROCEDURE).
Who is sponsoring clinical trial NCT02621151?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02621151 being conducted?
This trial has 5 study locations across Illinois, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.